2,4-dimethyl-6-[[(3S)-piperidin-3-yl]methoxy]pyrimidine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4-dimethyl-6-[[(3S)-piperidin-3-yl]methoxy]pyrimidine
• 化学式: C₁₂H₁₉N₃O
• 分子量: 221.302
• InChiKey: XJCMSLDKAOXJLN-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基溴化镁 、 2-Methylthiazolo[4,5-b]pyridine-5-carbaldehyde 、 2,4-dimethyl-6-[[(3S)-piperidin-3-yl]methoxy]pyrimidine 在 titanium(IV) isopropylate 作用下， 以 二氯甲烷 、 四氢呋喃 、 甲苯 为溶剂， 反应 22.0h， 以3%的产率得到5-[1-[(3S)-3-[(2,6-dimethylpyrimidin-4-yl)oxymethyl]piperidin-1-yl]ethyl]-2-methyl-[1,3]thiazolo[4,5-b]pyridine
  参考文献：
  名称：

  [EN] OGA INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS D'OGA

  摘要：

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。

  公开号：

  WO2019243528A1

文献信息

• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210115040A1

  公开（公告）日：2021-04-22

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243526A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.